A strategic model for developing vaccines against neglected diseases: An example of industry collaboration for sustainable development
Infectious diseases continue to disproportionately affect low- and middle-income countries (LMICs) and children aged <5 y. Developing vaccines against diseases endemic in LMICs relies mainly on strong public-private collaborations, but several challenges remain. We review the operating model of t...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-11-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2022.2136451 |
| _version_ | 1827806346404167680 |
|---|---|
| author | Francesco Berlanda Scorza Laura B. Martin Audino Podda Rino Rappuoli |
| author_facet | Francesco Berlanda Scorza Laura B. Martin Audino Podda Rino Rappuoli |
| author_sort | Francesco Berlanda Scorza |
| collection | DOAJ |
| description | Infectious diseases continue to disproportionately affect low- and middle-income countries (LMICs) and children aged <5 y. Developing vaccines against diseases endemic in LMICs relies mainly on strong public-private collaborations, but several challenges remain. We review the operating model of the GSK Vaccines Institute for Global Health (GVGH), which aims to address these challenges. The model involves i) selection of vaccine targets based on priority ranking for impact on global health; ii) development from design to clinical proof-of-concept; iii) transfer to an industrial partner, for further technical/clinical development, licensing, manufacturing, and distribution. Cost and risks associated with pre-clinical and early clinical development are assumed by GVGH, increasing the probability to make the vaccine more affordable in LMICs. A conjugate vaccine against typhoid fever, Vi-CRM197, has recently obtained WHO prequalification, within a year from licensure in India, demonstrating the success of the GVGH model for development and delivery of global health vaccines. |
| first_indexed | 2024-03-11T21:40:48Z |
| format | Article |
| id | doaj.art-916da275b051442ebd9b92372fa1a702 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T21:40:48Z |
| publishDate | 2022-11-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-916da275b051442ebd9b92372fa1a7022023-09-26T13:19:10ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2022-11-0118610.1080/21645515.2022.21364512136451A strategic model for developing vaccines against neglected diseases: An example of industry collaboration for sustainable developmentFrancesco Berlanda Scorza0Laura B. Martin1Audino Podda2Rino Rappuoli3GSK Vaccines Institute for Global HealthU.S. Pharmacopeial ConventionGSK Vaccines Institute for Global HealthGSK Vaccines Institute for Global HealthInfectious diseases continue to disproportionately affect low- and middle-income countries (LMICs) and children aged <5 y. Developing vaccines against diseases endemic in LMICs relies mainly on strong public-private collaborations, but several challenges remain. We review the operating model of the GSK Vaccines Institute for Global Health (GVGH), which aims to address these challenges. The model involves i) selection of vaccine targets based on priority ranking for impact on global health; ii) development from design to clinical proof-of-concept; iii) transfer to an industrial partner, for further technical/clinical development, licensing, manufacturing, and distribution. Cost and risks associated with pre-clinical and early clinical development are assumed by GVGH, increasing the probability to make the vaccine more affordable in LMICs. A conjugate vaccine against typhoid fever, Vi-CRM197, has recently obtained WHO prequalification, within a year from licensure in India, demonstrating the success of the GVGH model for development and delivery of global health vaccines.http://dx.doi.org/10.1080/21645515.2022.2136451vaccinetyphoid feverinfectious diseasesglobal healthlmics |
| spellingShingle | Francesco Berlanda Scorza Laura B. Martin Audino Podda Rino Rappuoli A strategic model for developing vaccines against neglected diseases: An example of industry collaboration for sustainable development Human Vaccines & Immunotherapeutics vaccine typhoid fever infectious diseases global health lmics |
| title | A strategic model for developing vaccines against neglected diseases: An example of industry collaboration for sustainable development |
| title_full | A strategic model for developing vaccines against neglected diseases: An example of industry collaboration for sustainable development |
| title_fullStr | A strategic model for developing vaccines against neglected diseases: An example of industry collaboration for sustainable development |
| title_full_unstemmed | A strategic model for developing vaccines against neglected diseases: An example of industry collaboration for sustainable development |
| title_short | A strategic model for developing vaccines against neglected diseases: An example of industry collaboration for sustainable development |
| title_sort | strategic model for developing vaccines against neglected diseases an example of industry collaboration for sustainable development |
| topic | vaccine typhoid fever infectious diseases global health lmics |
| url | http://dx.doi.org/10.1080/21645515.2022.2136451 |
| work_keys_str_mv | AT francescoberlandascorza astrategicmodelfordevelopingvaccinesagainstneglecteddiseasesanexampleofindustrycollaborationforsustainabledevelopment AT laurabmartin astrategicmodelfordevelopingvaccinesagainstneglecteddiseasesanexampleofindustrycollaborationforsustainabledevelopment AT audinopodda astrategicmodelfordevelopingvaccinesagainstneglecteddiseasesanexampleofindustrycollaborationforsustainabledevelopment AT rinorappuoli astrategicmodelfordevelopingvaccinesagainstneglecteddiseasesanexampleofindustrycollaborationforsustainabledevelopment AT francescoberlandascorza strategicmodelfordevelopingvaccinesagainstneglecteddiseasesanexampleofindustrycollaborationforsustainabledevelopment AT laurabmartin strategicmodelfordevelopingvaccinesagainstneglecteddiseasesanexampleofindustrycollaborationforsustainabledevelopment AT audinopodda strategicmodelfordevelopingvaccinesagainstneglecteddiseasesanexampleofindustrycollaborationforsustainabledevelopment AT rinorappuoli strategicmodelfordevelopingvaccinesagainstneglecteddiseasesanexampleofindustrycollaborationforsustainabledevelopment |